Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

E. H. Gisolf; C. Dreezen; S. A. Danner; J. L.F. Weel; G. J. Weverling; P. Reiss; G. J. Weverling; M. Duurvoort; E. Krijger; E. Brouwer; G. R. Visser; A. Klotz; C. Benschop; F. Wulfert; S. A. Danner; F. De Wolf; S. Jurriaans; P. Portegies; R. Colebunders; J. Pelgrom; H. Wijnants; A. DE Roo; K. Keersmaekers; M. Vandenbruane; D. Van Den Branden; T. James; F. Van Wanzeele; B. Van Der Gucht; M. E. Van Der Ende; J. Nouwen; R. Deenenkamp; D. Van Der Meyden; P. P. Koopmans; K. Brinkman; H. Ver Hofstede; B. Zomer; W. L. Blok; C. Ruissen; H. Sprenger; G. Law; P. Vander Meulen; C. Ten Veen; J. R. Juttmann; C. Vander Heul; R. Santegoets; B. Vander Ven; R. W.Ten Kate; M. Schoemaker; R. H. Kauffmann; J. M. Henrichs; A. Maat; E. Prins; C. H.H.Ten Napel; K. Pogany; T. Duyts; P. Simons; P. Lacor; A. De Waele; E. Van Wijngaarden; M. Lejeune; E. Van Wijngaarden; M. Lejeune; P. Nieuwkerk; M. Sprangers; M. Roos; R. Scholte; J. Dijkman; A. J. Japour; M. J. Borst; E. Van Leeuwen

doi:https://doi.org/10.1086/317449

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

E. H. Gisolf, C. Dreezen, S. A. Danner, J. L.F. Weel, G. J. Weverling, P. Reiss, G. J. Weverling, M. Duurvoort, E. Krijger, E. Brouwer, G. R. Visser, A. Klotz, C. Benschop, F. Wulfert, S. A. Danner, F. De Wolf, S. Jurriaans, P. Portegies, R. Colebunders, J. PelgromH. Wijnants, A. DE Roo, K. Keersmaekers, M. Vandenbruane, D. Van Den Branden, T. James, F. Van Wanzeele, B. Van Der Gucht, M. E. Van Der Ende, J. Nouwen, R. Deenenkamp, D. Van Der Meyden, P. P. Koopmans, K. Brinkman, H. Ver Hofstede, B. Zomer, W. L. Blok, C. Ruissen, H. Sprenger, G. Law, P. Vander Meulen, C. Ten Veen, J. R. Juttmann, C. Vander Heul, R. Santegoets, B. Vander Ven, R. W.Ten Kate, M. Schoemaker, R. H. Kauffmann, J. M. Henrichs, A. Maat, E. Prins, C. H.H.Ten Napel, K. Pogany, T. Duyts, P. Simons, P. Lacor, A. De Waele, E. Van Wijngaarden, M. Lejeune, E. Van Wijngaarden, M. Lejeune, P. Nieuwkerk, M. Sprangers, M. Roos, R. Scholte, J. Dijkman, A. J. Japour, M. J. Borst, E. Van Leeuwen

Internal Medicine (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

92 Citations (Scopus)

Abstract

Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3-23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5-16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by >50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.

Original language	English
Pages (from-to)	1234-1239
Number of pages	6
Journal	Clinical Infectious Diseases
Volume	31
Issue number	5
DOIs	https://doi.org/10.1086/317449
Publication status	Published - 2000

Keywords

AMC wi-eigen

Access to Document

https://doi.org/10.1086/317449

https://pure.uva.nl/ws/files/3056536/12405_87325y.pdf

Cite this

Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L. F., Weverling, G. J., Reiss, P., Weverling, G. J., Duurvoort, M., Krijger, E., Brouwer, E., Visser, G. R., Klotz, A., Benschop, C., Wulfert, F., Danner, S. A., Wolf, F. D., Jurriaans, S., Portegies, P., Colebunders, R., ... Leeuwen, E. V. (2000). Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clinical Infectious Diseases, 31(5), 1234-1239. https://doi.org/10.1086/317449

@article{de1cd8b61587485a86caf4d2dbce383b,

title = "Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine",

abstract = "Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3-23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5-16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by >50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.",

keywords = "AMC wi-eigen",

author = "Gisolf, {E. H.} and C. Dreezen and Danner, {S. A.} and Weel, {J. L.F.} and Weverling, {G. J.} and P. Reiss and Weverling, {G. J.} and M. Duurvoort and E. Krijger and E. Brouwer and Visser, {G. R.} and A. Klotz and C. Benschop and F. Wulfert and Danner, {S. A.} and Wolf, {F. De} and S. Jurriaans and P. Portegies and R. Colebunders and J. Pelgrom and H. Wijnants and {DE Roo}, A. and K. Keersmaekers and M. Vandenbruane and Branden, {D. Van Den} and T. James and Wanzeele, {F. Van} and Gucht, {B. Van Der} and {Van Der Ende}, {M. E.} and J. Nouwen and R. Deenenkamp and {Van Der Meyden}, D. and Koopmans, {P. P.} and K. Brinkman and {Ver Hofstede}, H. and B. Zomer and Blok, {W. L.} and C. Ruissen and H. Sprenger and G. Law and Meulen, {P. Vander} and Veen, {C. Ten} and Juttmann, {J. R.} and Heul, {C. Vander} and R. Santegoets and Ven, {B. Vander} and Kate, {R. W.Ten} and M. Schoemaker and Kauffmann, {R. H.} and Henrichs, {J. M.} and A. Maat and E. Prins and Napel, {C. H.H.Ten} and K. Pogany and T. Duyts and P. Simons and P. Lacor and Waele, {A. De} and Wijngaarden, {E. Van} and M. Lejeune and Wijngaarden, {E. Van} and M. Lejeune and P. Nieuwkerk and M. Sprangers and M. Roos and R. Scholte and J. Dijkman and Japour, {A. J.} and Borst, {M. J.} and Leeuwen, {E. Van}",

year = "2000",

doi = "https://doi.org/10.1086/317449",

language = "English",

volume = "31",

pages = "1234--1239",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

Gisolf, EH, Dreezen, C, Danner, SA, Weel, JLF, Weverling, GJ, Reiss, P, Weverling, GJ, Duurvoort, M, Krijger, E, Brouwer, E, Visser, GR, Klotz, A, Benschop, C, Wulfert, F, Danner, SA, Wolf, FD, Jurriaans, S, Portegies, P, Colebunders, R, Pelgrom, J, Wijnants, H, DE Roo, A, Keersmaekers, K, Vandenbruane, M, Branden, DVD, James, T, Wanzeele, FV, Gucht, BVD, Van Der Ende, ME, Nouwen, J, Deenenkamp, R, Van Der Meyden, D, Koopmans, PP, Brinkman, K, Ver Hofstede, H, Zomer, B, Blok, WL, Ruissen, C, Sprenger, H, Law, G, Meulen, PV, Veen, CT, Juttmann, JR, Heul, CV, Santegoets, R, Ven, BV, Kate, RWT, Schoemaker, M, Kauffmann, RH, Henrichs, JM, Maat, A, Prins, E, Napel, CHHT, Pogany, K, Duyts, T, Simons, P, Lacor, P, Waele, AD, Wijngaarden, EV, Lejeune, M, Wijngaarden, EV, Lejeune, M, Nieuwkerk, P, Sprangers, M, Roos, M, Scholte, R, Dijkman, J, Japour, AJ, Borst, MJ & Leeuwen, EV 2000, 'Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine', Clinical Infectious Diseases, vol. 31, no. 5, pp. 1234-1239. https://doi.org/10.1086/317449

TY - JOUR

T1 - Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

AU - Gisolf, E. H.

AU - Dreezen, C.

AU - Danner, S. A.

AU - Weel, J. L.F.

AU - Weverling, G. J.

AU - Reiss, P.

AU - Weverling, G. J.

AU - Duurvoort, M.

AU - Krijger, E.

AU - Brouwer, E.

AU - Visser, G. R.

AU - Klotz, A.

AU - Benschop, C.

AU - Wulfert, F.

AU - Danner, S. A.

AU - Wolf, F. De

AU - Jurriaans, S.

AU - Portegies, P.

AU - Colebunders, R.

AU - Pelgrom, J.

AU - Wijnants, H.

AU - DE Roo, A.

AU - Keersmaekers, K.

AU - Vandenbruane, M.

AU - Branden, D. Van Den

AU - James, T.

AU - Wanzeele, F. Van

AU - Gucht, B. Van Der

AU - Van Der Ende, M. E.

AU - Nouwen, J.

AU - Deenenkamp, R.

AU - Van Der Meyden, D.

AU - Koopmans, P. P.

AU - Brinkman, K.

AU - Ver Hofstede, H.

AU - Zomer, B.

AU - Blok, W. L.

AU - Ruissen, C.

AU - Sprenger, H.

AU - Law, G.

AU - Meulen, P. Vander

AU - Veen, C. Ten

AU - Juttmann, J. R.

AU - Heul, C. Vander

AU - Santegoets, R.

AU - Ven, B. Vander

AU - Kate, R. W.Ten

AU - Schoemaker, M.

AU - Kauffmann, R. H.

AU - Henrichs, J. M.

AU - Maat, A.

AU - Prins, E.

AU - Napel, C. H.H.Ten

AU - Pogany, K.

AU - Duyts, T.

AU - Simons, P.

AU - Lacor, P.

AU - Waele, A. De

AU - Wijngaarden, E. Van

AU - Lejeune, M.

AU - Wijngaarden, E. Van

AU - Lejeune, M.

AU - Nieuwkerk, P.

AU - Sprangers, M.

AU - Roos, M.

AU - Scholte, R.

AU - Dijkman, J.

AU - Japour, A. J.

AU - Borst, M. J.

AU - Leeuwen, E. Van

PY - 2000

Y1 - 2000

N2 - Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3-23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5-16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by >50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.

AB - Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3-23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5-16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by >50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.

KW - AMC wi-eigen

UR - http://www.scopus.com/inward/record.url?scp=0034457420&partnerID=8YFLogxK

U2 - https://doi.org/10.1086/317449

DO - https://doi.org/10.1086/317449

M3 - Article

C2 - 11073757

SN - 1058-4838

VL - 31

SP - 1234

EP - 1239

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

Abstract

Keywords

Access to Document

Other files and links

Cite this